ReviewPathogens (Basel, Switzerland)2024
Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens.
Review in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Codelivering Polymyxin B and Phage Using Thermosensitive Hydrogel for Treating Carbapenem-ResistantACS omega · 2026Article
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Mechanism ofMicroorganisms · 2026Article
- Synergy antibacterial effects of lytic phage vB_AbaA_LLY and levofloxacin against KL2 and KL160 Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Isolation and Characterization of Two Bacteriophages InfectingMicroorganisms · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape.Journal of clinical microbiology · 2026Review
- Recurrent Urinary Tract Infections in a Patient with Diffuse Large B-Cell Lymphoma and Severe COVID-19: A Single Case of Suspected Immunosuppression Where Antibacterial Therapy Was Not Enough.Antibiotics (Basel, Switzerland) · 2026Article
- Pathological networks and multi-target interventions in sepsis-associated acute lung injury: from pathogen-host interactions to gut-lung axis regulation.Frontiers in immunology · 2026Review
- Advances in mycobacteriophage research: from lytic mechanisms to one health applications.Frontiers in cellular and infection microbiology · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Small siphophage binding to an open state of the LptDE outer membrane lipopolysaccharide translocon.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Phage Therapy for Bone and Joint Infections: Towards Clinical Translation.Antibiotics (Basel, Switzerland) · 2025Review
- Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules.The Journal of antimicrobial chemotherapy · 2025Review
- Review
- Phage Therapy as a Novel Alternative to Antibiotics Through Adaptive Evolution and Fitness Trade-Offs.Antibiotics (Basel, Switzerland) · 2025Review
- Integrative In Silico and Experimental Characterization of Endolysin LysPALS22: Structural Diversity, Ligand Binding Affinity, and Heterologous Expression.International journal of molecular sciences · 2025Article
- Beyond the Usual Suspects:Tropical medicine and infectious disease · 2025Review
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continued rise in antimicrobial resistance poses a serious threat to public health worldwide. The use of phages that can have bactericidal activity without disrupting the normal flora represents a promising alternative treatment method. This practice has been successfully applied for decades, mainly in Eastern Europe, and has recently been used as an emergency therapy for compassionate care in the United States. Here, we provide a comprehensive review of the pre-clinical and clinical applications of phage therapy concerning three major Gram-negative pathogens:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.